Updated:
EUDA Health Holdings Ltd
EUDA Health Holdings Ltd is a Singapore-based digital health platform founded by Dr. Kelvin Chen, trading on Nasdaq after a 2022 SPAC merger.
EUDA Health Holdings Ltd
EUDA Health Holdings Ltd was formed to consolidate digital health assets across Asia, led by CEO Dr. Kelvin Chen and COO Dr. Chong Chia Tai. The company went public on the Nasdaq in July 2022 through a merger with a special-purpose acquisition company (SPAC), raising capital to scale its telemedicine and AI diagnostics offerings. Its founding team combines medical and operational experience from public hospitals and regional healthcare startups. The firm's strategy centers on digital primary-care platforms, deploying an AI-powered symptom checker and virtual consultation system branded as EUDA. It targets underserved populations in Southeast Asia, with an initial focus on Malaysia, Indonesia, and Thailand. Asset classes include healthcare technology infrastructure, telemedicine software, and AI/ML clinical tools. The platform processes patient data for triage, chronic-disease management, and pharmacy integration, with revenue generated through provider fees and enterprise contracts. Confirmed commercial partners include public health agencies in Southeast Asia (per public filings, 2023). Geographic footprint spans Singapore (headquarters) and operational presence in Malaysia and Indonesia. As of 2025, EUDA Health lists fewer than 50 employees across its offices in Singapore and Kuala Lumpur (per public record). The company does not disclose AUM or deployment figures; its balance sheet shows it operates as an operating company rather than a family office or asset manager. An adjacent entity, EUDA Foundation, is noted in corporate filings as a philanthropic arm focused on digital health equity in rural Asia. A recent operational event: In October 2024, EUDA Health received a notice of non-compliance with Nasdaq's minimum bid price requirement, which it subsequently addressed via a reverse stock split (per Nasdaq filing, October 2024). EUDA Health's structural differentiator is its public-company governance framework combined with a mission-driven focus on emerging-market digital health. Unlike venture-backed health-tech startups, EUDA must comply with SEC reporting and shareholder transparency requirements, which limits its ability to engage in opaque investment vehicles. The firm's succession and governance structure remains tightly controlled by its founding medical professionals, with no external institutional investors disclosed on its board as of 2025.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Principals
Dr. Kelvin Chen
Chief Executive Officer
Dr. Chong Chia Tai
Chief Operating Officer
Sector focus
Frequently asked questions
Who runs investment decisions at EUDA Health Holdings Ltd?
Dr. Kelvin Chen, CEO, and Dr. Chong Chia Tai, COO, oversee strategic decisions at EUDA Health Holdings Ltd. The company's board included Dr. Chen as chairman as of 2024. The leadership team is composed primarily of medical and operational professionals rather than dedicated investment managers, reflecting the firm's operating-company structure (per public filings, 2024).
How does EUDA Health source proprietary deal flow or technology?
EUDA Health develops its AI-powered telemedicine platform internally and licenses certain clinical algorithms from academic medical centers in Southeast Asia. The company has not disclosed a formal venture or investment arm; its growth relies on direct enterprise contracts with public health agencies and hospital groups (per public filings, 2023).
Is EUDA Health structured as a single family office, multi-family office, or operating company?
EUDA Health Holdings Ltd is an operating company publicly traded on the Nasdaq (ticker: EUDA). It is not structured as a family office. The firm does not manage outside capital and operates as a for-profit corporation focused on digital health services, with a business model generating revenue from telemedicine consultations and AI triage tools (per SEC filings, 2023).
What investment stages or asset classes does EUDA Health target?
EUDA Health operates in the digital health infrastructure and services space, not as an investment firm. Its capital is deployed internally for platform development, clinical trials, and geographic expansion. The company does not participate in external fund commitments or direct investments in other firms. Its focus is on late-stage technology deployment in primary care (per company communications, 2023).
Which sectors does EUDA Health explicitly avoid?
EUDA Health's public filings and leadership remarks indicate no explicit exclusions, but the company concentrates exclusively on digital health, telemedicine, and AI diagnostics. It has not entered adjacent sectors such as pharmaceutical manufacturing, medical devices, or health insurance. Its stated focus is on underserved Asian markets, avoiding high-cost Western healthcare systems (per public record, 2023).
Does EUDA Health maintain philanthropic structures, and how are they separated?
EUDA Health incorporated the EUDA Foundation as a separate legal entity focused on digital health equity in rural parts of Asia. The foundation is funded through corporate donations and is governed independently, with advisory board members distinct from the operating company's board (per corporate filings, 2023).
What is EUDA Health's known posture on co-investments alongside external GPs?
EUDA Health does not engage in co-investments with external general partners. As a publicly traded operating company, its capital allocation decisions are board-driven and directed toward organic growth. There is no public record of the firm participating in syndicated deals, SPVs, or fund investments (per SEC filings, 2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: